Myriad Genetics Inc (NASDAQ: MYGN) has reported E.P.S. of $-0.36 for its fourth fiscal quarter (ending December 31) versus $-0.52 for the same period a year ago. Relative to the consensus estimate of $0.01, this was a shortfall of $-0.37. For the latest four quarters through December 31, E.P.S. were $-3.18 compared to $-1.39 a year ago.
Recent Price Action
Myriad Genetics Inc (NASDAQ: MYGN) stock closed at $23.50 on 2/27/24 after a large increase of 2.5%. Moreover, this advance was accompanied by unusually high trading volume at 159% of normal. The stock has risen 1.1% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, MYGN is expected to be a modest Value Builder.
Myriad Genetics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Myriad Genetics has a poor Power Rating of 25 and a poor Appreciation Score of 15, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment